N-Methyl-PPPA — BrandWiki

N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed.[1][2][3] It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.[1][2][3]

References

Neurobiology of Depression CRC Press, 9 September 2011^
Drug Discovery: A History John Wiley & Sons, 31 October 2005^
Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication Life Sciences, 1995^